Furthermore, luteolin has been shown to enhance the sensitivity of MDA-MB-231 breast cancer cells to doxorubicin [137] and paclitaxel [138] by inhibiting Nrf2 signaling and blocking STAT3, respectively. Here, STAT3 is linked to breast carcinoma.